UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): April 24, 2025 |
Rani Therapeutics Holdings, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
001-40672 |
86-3114789 |
(State or other jurisdiction
of incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
|
|
|
|
|
2051 Ringwood Avenue |
|
San Jose, California |
|
95131 |
(Address of principal executive offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: (408) 457-3700 |
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s) |
|
Name of each exchange on which registered
|
Class A common stock, par value $0.0001 per share |
|
RANI |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 24, 2025, Laureen DeBuono notified the Board of Directors (“Board”) of Rani Therapeutics Holdings, Inc. (the “Company”) that she has decided to retire from the Board effective immediately. Ms. DeBuono 's decision was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. At the time of her resignation, Ms. DeBuono served as a member of the Audit Committee and Compensation Committee of the Board. Following Ms. DeBuono’s retirement from the Board, the Board reconstituted the committees of the Board as follows:
Audit Committee Lisa Rometty (Chair)
Jean-Luc Butel
Maulik Nanavaty
Compensation Committee Maulik Nanavaty (Chair)
Dennis Ausiello
Nominating and Corporate Jean-Luc Butel (Chair)
Governance Committee Dennis Ausiello
Lisa Rometty
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
|
Exhibit Number |
|
Exhibit Description |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
Rani Therapeutics Holdings, Inc. |
|
|
|
|
Date: |
April 30, 2025 |
By: |
/s/ Svai Sanford |
|
|
|
Svai Sanford
Chief Financial Officer |
